XTLB - XTL Biopharmaceuticals Ltd. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

XTLB

XTL BIOPHARMACEUTICALS LTD.

NASDAQ

$2.47

▼ DOWN 4.26% (-0.11)

KEY STATISTICS

Market Cap$2.34 M

52w High$10.28

52w Low$2.01

Dividend Yield—

Frequency—

P/E-12.35

Volume8.11K

Shares Out.946.24K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Noam Band

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 1, 2005

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

SPLIT RECORD

DATE	TYPE	RATIO
2026-03-25	Reverse	1:4
2025-12-24	Reverse	1:4
2017-02-10	Reverse	1:5
2012-10-04	Reverse	1:10

PRICE

$2.47 ▼ DOWN 4.26% (−$0.11)

OVERLAYS

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com ↗

XTL Biopharmaceuticals Ltd. develops autoimmune disease treatments, with lead candidate hCDR1 for lupus and Sjogren's, under a licensing agreement with Yeda, and is based in Ramat Gan, Israel.

INDUSTRY

Biotechnology

A PRODUCT XTL BIOPHARMACEUTICALS LTD. IS KNOWN FOR

BA-102

BA-102, an FDA-designated orphan drug in preclinical development by XTL Biopharmaceuticals for Phelan-McDermid Syndrome, a rare neurodevelopmental disorder linked to ASD, with human trials planned for 2026.